Lakewood-Amedex Finalizes Highly Dilutive Series C Offering and Conversions, Doubling Share Count Amid Going Concern Warning

summarizeSummary

Lakewood-Amedex has completed a highly dilutive Series C financing and converted all preferred stock and convertible debt, significantly increasing its common share count, while still facing a "going concern" warning.

check_boxKey Events · Financing and Capital Events · LABT

• Massive Dilution Confirmed

  The company finalized the issuance of shares from a $6.8 million Series C financing and the automatic conversion of all preferred stock and convertible notes, leading to a substantial increase in common shares outstanding.

• Ongoing Going Concern Warning

  Despite the recent capital infusion, the company continues to express substantial doubt about its ability to fund operations beyond Q4 2026.

• Deeply Discounted Capital Raise

  The Series C Preferred Stock was issued at a 20% original issue discount, reflecting the challenging terms required to secure financing.

• Internal Control Weaknesses Identified

  Material weaknesses in internal controls over financial reporting were disclosed, including limited documentation and segregation of duties.

auto_awesomeAnalysis · LABT · Life Sciences

This filing confirms the actual issuance of shares from a highly dilutive Series C Convertible Preferred Stock financing and the automatic conversion of all outstanding preferred stock and convertible notes. This event significantly increases the common share count, effectively doubling it. Despite raising $6.8 million, the company continues to carry a "going concern" warning, indicating ongoing financial instability and a need for further capital beyond Q4 2026. The Series C financing was at a deep discount, reflecting the company's challenging financial position.